MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-14-2024
Acorda Therapeutics Retained Earnings 2011-2026 | ACOR
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.19 B | -936 M | -870 M | -766 M | -667 M | -394 M | -455 M | -244 M | -209 M | -220 M | -238 M | -255 M | -409 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -209 M | -1.19 B | -527 M |
Quarterly Retained Earnings Acorda Therapeutics
| 2024-Q1 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.22 B | -953 M | -936 M | -955 M | -942 M | -895 M | -870 M | -850 M | -823 M | -800 M | -766 M | -766 M | -766 M | -766 M | -667 M | -667 M | -667 M | -667 M | -394 M | -394 M | -394 M | -394 M | -455 M | -455 M | -455 M | -455 M | -244 M | -244 M | -244 M | -244 M | -209 M | -209 M | -209 M | -209 M | -220 M | -220 M | -220 M | -220 M | -238 M | -238 M | -238 M | -238 M | -255 M | -255 M | -255 M | -255 M | -409 M | -409 M | -409 M | -409 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -209 M | -1.22 B | -493 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M |  USA |
 |
AbbVie
ABBV
|
-15.5 B | $ 232.08 | 3.29 % | $ 411 B | USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.61 | 0.56 % | $ 1.08 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-750 M | $ 5.12 | -1.54 % | $ 109 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.66 | -0.85 % | $ 773 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
-2.2 B | $ 24.56 | -0.32 % | $ 4.07 B | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Achieve Life Sciences
ACHV
|
-166 M | $ 4.56 | -3.59 % | $ 90.4 M | USA |
 |
AC Immune SA
ACIU
|
-133 M | $ 2.93 | -1.01 % | $ 229 M |  Schweiz |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aclaris Therapeutics
ACRS
|
-968 M | $ 2.87 | -8.31 % | $ 352 M | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-311 M | $ 2.96 | -4.67 % | $ 167 M | China |
 |
ADC Therapeutics SA
ADCT
|
-925 M | $ 4.1 | -0.73 % | $ 105 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
-82 M | $ 2.53 | - | $ 16.4 M | USA |
 |
ADMA Biologics
ADMA
|
-162 M | $ 15.57 | 2.57 % | $ 3.71 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-1.36 B | $ 16.02 | -2.67 % | $ 2.43 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-168 M | $ 0.46 | -4.63 % | $ 6.06 K | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Agenus
AGEN
|
-1.96 B | $ 3.33 | -0.89 % | $ 1.19 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-562 M | $ 30.23 | 0.83 % | $ 1.75 B | USA |
 |
AIM ImmunoTech
AIM
|
-381 M | $ 0.91 | -8.59 % | $ 43.8 M | USA |
 |
Akebia Therapeutics
AKBA
|
-1.68 B | $ 1.31 | -0.76 % | $ 337 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-247 M | $ 0.24 | -8.87 % | $ 5.73 B | Britain |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Aldeyra Therapeutics
ALDX
|
-484 M | $ 5.46 | -0.73 % | $ 328 M | USA |
 |
Alector
ALEC
|
-972 M | $ 2.43 | -5.08 % | $ 250 M | USA |
 |
Aligos Therapeutics
ALGS
|
-487 M | $ 7.03 | -6.27 % | $ 452 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Alkermes plc
ALKS
|
-735 M | $ 30.1 | -2.05 % | $ 4.96 B |  Irlanda |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Allogene Therapeutics
ALLO
|
-1.56 B | $ 2.78 | 1.83 % | $ 436 M | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 332.92 | 0.51 % | $ 43.6 B | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Altimmune
ALT
|
-561 M | $ 4.31 | -3.36 % | $ 306 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-621 M | $ 2.11 | -10.21 % | $ 110 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Amgen
AMGN
|
-25.1 B | $ 388.16 | 2.33 % | $ 209 B | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |